Azitra Inc
AMEX:AZTR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Azitra Inc
Interest Income Expense
Azitra Inc
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Azitra Inc
AMEX:AZTR
|
Interest Income Expense
$62.6k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$2.7B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-12%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$224m
|
CAGR 3-Years
48%
|
CAGR 5-Years
39%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$732m
|
CAGR 3-Years
20%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$466.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$1.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
Azitra Inc
Glance View
Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The company is headquartered in Branford, Connecticut and currently employs 10 full-time employees. The company went IPO on 2023-06-16. The firm is focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. Its platform includes a microbial library comprised of approximately 1,500 bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its product ATR-12 is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its product ATR-04 is a genetically modified strain of S. epidermidis for treating the papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
See Also
What is Azitra Inc's Interest Income Expense?
Interest Income Expense
62.6k
USD
Based on the financial report for Dec 31, 2025, Azitra Inc's Interest Income Expense amounts to 62.6k USD.
What is Azitra Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
16%
Over the last year, the Interest Income Expense growth was -43%.
